Press coverage about ITUS (NASDAQ:ITUS) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ITUS earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the business services provider an impact score of 47.8226569489629 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of ITUS (ITUS) traded down $0.03 during trading on Wednesday, hitting $2.63. 124,200 shares of the stock were exchanged, compared to its average volume of 726,876. ITUS has a 1-year low of $0.60 and a 1-year high of $5.70.

Separately, ValuEngine lowered shares of ITUS from a “hold” rating to a “sell” rating in a report on Thursday, December 7th.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at

About ITUS

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream.

Insider Buying and Selling by Quarter for ITUS (NASDAQ:ITUS)

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with's FREE daily email newsletter.